Dexamethasone Treatment for Covid-19 Pneumonia

Abstract

Dexamethasone is currently one of the few treatments that has been shown to be effective in patients with moderate or severe SARSCoV-2 pneumonia. A dose of 6 mg/day of dexamethasone base for 10 days has been shown to significantly reduce mortality in these patients. In Argentina, there are several commercial presentations of dexamethasone (dexamethasone  sodium phosphate and dexamethasone phosphate acid). Therefore, it is important to know their equivalence in relation to  dexamethasone base, in order to ensure the administration of 6 mg/day, that has been shown to decrease mortality.